Fig. 3 | British Journal of Cancer

Fig. 3

From: Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

Fig. 3The alternative text for this image may have been generated using AI.

Subgroup analysis of 18-week progression-free survival (PFS). Hormone receptor negative, prior lapatinib response (CR or PR) and the last administration of lapatinib within 6 months favoured LV treatment but it did not show statistical significance

Back to article page